Zacks Investment Research downgraded shares of Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) from a buy rating to a hold rating in a research note released on Monday.
According to Zacks, “Actinium Pharmaceuticals, Inc. is a biopharmaceutical company. It specializes in the development of cancer drugs. The company’s principal product candidates under different developmental stages include Actimab-A for the treatment of acute myeloid leukemia in elderly patients and Iomab-B used to condition the bone marrow of patients. Actinium Pharmaceuticals, Inc. is based in New York. “
ATNM has been the topic of a number of other reports. HC Wainwright reissued a buy rating and set a $6.00 target price on shares of Actinium Pharmaceuticals in a report on Monday, October 23rd. Maxim Group began coverage on shares of Actinium Pharmaceuticals in a report on Thursday, September 14th. They set a buy rating and a $3.00 target price on the stock. Roth Capital reissued a buy rating and set a $6.00 target price on shares of Actinium Pharmaceuticals in a report on Monday, October 23rd. Finally, B. Riley set a $3.00 target price on shares of Actinium Pharmaceuticals and gave the stock a buy rating in a report on Tuesday, December 12th. Five research analysts have rated the stock with a buy rating, The company has an average rating of Buy and an average target price of $3.75.
ILLEGAL ACTIVITY NOTICE: “Actinium Pharmaceuticals (ATNM) Lowered to “Hold” at Zacks Investment Research” was originally posted by Markets Daily and is the property of of Markets Daily. If you are reading this story on another website, it was illegally stolen and republished in violation of US and international copyright laws. The legal version of this story can be accessed at https://www.themarketsdaily.com/2018/01/11/actinium-pharmaceuticals-atnm-lowered-to-hold-at-zacks-investment-research.html.
Actinium Pharmaceuticals Company Profile
Actinium Pharmaceuticals, Inc (Actinium) is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. The Company is engaged in developing therapies for diseases using its alpha particle immunotherapy platform and other related technologies. The Company’s products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.